Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Feb
22
Today In Oncology
FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma
Survival Outcomes With or Without Bilateral Risk-Reducing Mastectomy in BRCA1/BRCA2 Pathogenic Variant Carriers
CLL/SLL FDA Approves Combination of Acalabrutinib and Venetoclax
Metastasis-Directed Therapy in Oligometastatic Prostate Cancer
AI Tool Classifies Pediatric Brain Tumors via Liquid Biopsy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo